Discovery of Peptide-Based Antitoxins against Neurotoxins from Green and Black Mamba (Dendroaspis Family)

Jappe, Emma Christine; Munk, Andreas; Laustsen, Andreas Hougaard; Engmark, Mikael

Publication date:
2014

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Snakebite – A neglected threat to public health

Globally, more than 5.5 million people are bitten by venomous snakes every year, leading to an estimated 125,000 deaths and 3 times as many amputations [1, 2, 3]. The problem is most prevalent in Sub-Saharan Africa where affordability of antivenom is low, resulting in only 2% of snakebite victims receiving treatment [4, 5]. Since the introduction of antivenoms in the 1890s, only modest advances in antivenom technology and production have been made. Current antivenoms are, therefore, still being produced by immunisation of large ruminants, typically horses, with snake venoms and subsequently bleeding them to collect blood comprising venom-specific antibodies [4]. The incompatibility of these antivenoms with the human immune system can lead to serious adverse effects [1, 5]. A novel approach is needed in order to introduce safer, cheaper and more efficacious antivenoms that are compatible with the human immune system to the market.

We attempt to discover cross-reactive, peptide-based antivenoms against the structurally similar dendrotoxins o-dendrotoxin (o-Dtx, UniProtKB P00990), isolated from Dendroaspis angusticeps (Green mamba), and dendrotoxin I (Dtx I, UniProtKB P00979) from Dendroaspis polylepis (Black mamba) by phage display [5, 6]. Cross-reactive antivenoms with the ability to neutralise several toxins are of interest to antivenom development, since only a few cross-reactive antivenoms would be needed to neutralise a complete snake venom [6].

Method – Identification of binders with phage display

Initially, sequence alignment using the protein Needleman-Wunsch algorithm from EMBL-EBI was performed (Figure 3). Additionally, 3D structural models of the two toxins were constructed and compared. The structure of o-Dtx was based upon the available X-ray crystallographic structure with PDB entry 1DTX whilst the structure of Dtx I was estimated based upon a model of the Kunitz-type serine protease inhibitor (PDB entry 3BHY), isolated from Pseudonaja textilis (brown snake) using the Bioinformatics Toolkit developed by the Max-Planck Institute, Tübingen (Figure 3).

Figure 3: Surface models and overlapping cartoon models of o-dendrotoxin (o-Dtx) and dendrotoxin I (Dtx I) from D. angusticeps and D. polylepis, respectively, illustrating the largely similar secondary and tertiary structures of the two toxins. Models are drawn in PyMOL. Sequence similarity of 90% is observed when performing sequence alignment using the protein Needleman-Wunsch algorithm from EMBL-EBI.

Phage display was applied to discover binders to Dtx I and o-Dtx (Figure 2). Phage display is a screening technique, where a library of peptides is engineered to be expressed on the surface of bacteria by genetic fusion with a phage coat protein [7]. In order to identify specific binders, the mammalian snake venom is attached to plate wells (Roche-Boehringer plate) and, subsequently, the phage library is added to the wells. Phages that display a relevant peptide on their coat will be retained whilst unbound phages will be washed away. Iterative rounds of binding result in amplification of the phages expressing high-affinity peptides [7].

Results – Cross-reactivity based on similarity

Based on ELISA, strong binding to Dtx I was observed for the polyclonal phage library after the third round of panning (Figure 4), yet randomly selected monodonal phages did not show strong binding to Dtx I (Figure 5). It was observed that the polyclonal phage library also bound to o-Dtx (data not shown), indicating a high degree of cross-reactivity. This was anticipated by the bioinformatics modeling of the dendrotoxins, illustrating a high degree of similarity in both their primary, secondary, and tertiary structures (Figure 3).

Figure 5: ELISA results (Absorbance at 490 nm) showing the signal ratio between binding to Dtx I and the PBS + skim milk control for 10 selected phage monoclones from the third round of panning. An additional 20 phage monoclines were selected and tested for binding to Dtx I (data not shown); however, better binders were not observed. The best binder is Phage Monocline 8, which shows some degree of binding, but only a specificity of 2.1 for Dtx I vs. the PBS + skim milk control.

Outlook – Discovery of antivenoms for mamba toxins

Polynodal phages with strong binding affinity, high specificity, yet displaying cross-reactivity, were discovered using phage display. However, due to time limitations, no individual monoclonal phage was found to have both high affinity and show selectivity towards the toxins. Subsequent steps could include further analysis of other monoclonal phages or repetition of the fourth round of panning in order to attempt to amplify phages with high affinity and specificity. If a high-affinity toxin binder were to be identified, this binder could 1) be applied as a peptide-based antivenom, 2) be used to create a peptidomimetic antivenom or 3) be grafted onto an antibody as a CDR replacement, paving the way for safer and more efficacious antivenoms.

References


Contact information

emaj@bio.dtu.dk / (45) 5561 6755, antmunk@hotmail.com / (45) 2227 0444

Acknowledgement

Collaborators: Jonas Johansen (KU), Grethe Sørgaard (KU), Maiken Ravné (KU), Alexandra Bak Jakobsen (CBS).

Financial support: Department of Drug Design and Pharmacology, University of Copenhagen